Drug Firms Will Benefit From Cautious Estimates Of Part D Impact – Analyst
Executive Summary
Drug manufacturers' conservative estimates about the impact of the Medicare prescription drug benefit will pay off in 2006, Alliance analyst Norm Fidel suggested at the JP Morgan Healthcare conference Jan. 12